GJB2 and head and neck squamous cell carcinoma: Contemporary research in oncology indicates that Sal B harbors the potential to impede the proliferation of neoplastic cells across a diverse array of malignancies, including but not limited to, head and neck squamous cell carcinoma, non‐small cell lung cancer, and breast cancer.[31, 32] In our study, we found Sal B may be a new potential drug targeting GJB2 and provides new ideas for enhancing the effect of immunotherapy in HCC.